 |
 |
 |
Home |
| Dr. Jonathan Hepple Partner, Seroba Kernel |
 |
| Dr. Jonathan Hepple is a Partner of Seroba Kernel Life Sciences Limited and Partner at Rosetta Capital (London). Jonathan has been working with Seroba since 2003. At Rosetta, Jonathan manages portfolio investments in Tranzyme (USA), Ambrilia (Canada) and Zealand Pharma (Denmark). Jonathan co-founded BioScience Managers Ltd, since re-named as Rosetta Capital Ltd, in February 2001 following his tenure at Rothschild (1998-2001). Jonathan joined Rothschild as a biotechnology investment analyst and was a member of the multidisciplinary team responsible for the management of Biotechnology Investments Limited (“BIL”) and the International Biotechnology Trust (“IBT”). During his tenure at Rothschild, the BIL NAV grew to $600 million and IBT’s NAV grew to over £350 million. At Rothschild, Jonathan was responsible for the scientific evaluation of investment opportunities and the monitoring of portfolio companies. Prior to his PhD, Jonathan spent a year at British Biotechnology plc. Jonathan received a PhD from Cambridge University in 1997 and a BA from Oxford University in 1992. |
|
Kernel Management Partners Limited, trading as Kernel Capital, is regulated by the Central Bank of Ireland. |